Chinese cancer drug developer Biostar closes $135m pre-IPO round

Chinese cancer drug developer Biostar closes $135m pre-IPO round

26 November, 2020

anti-tumour Biostar Efung Capital Matrix Partners China

Printed by Unregistered user on Tue, 29 Jul 2025 07:17:45 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Boyu-backed Chinese cancer drug developer Antengene raises $361m in Hong Kong IPO

Chinese drug discovery firm Hinova closes $147m Series C

Read more from Greater China

HK’s Flow Capital Partners launches $125m credit fund, expands Asia focus

China’s FountainVest to buy major stake in Italy’s EuroGroup Laminations